PharmaCyte Biotech to Present Cancer and Diabetes Therapies at 2016 BIO International Convention
June 07 2016 - 9:20AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, today announced that its Chief
Executive Officer, Kenneth L. Waggoner, will present PharmaCyte’s
therapies for cancer and diabetes at this year’s BIO International
Convention (BIO). Meetings have been scheduled with big pharma
potential investors, strategic partners and the media. The 2016 BIO
International Convention is being held at the Moscone Center in San
Francisco June 6-9, 2016.
PharmaCyte’s Chief Executive Officer, Kenneth L.
Waggoner, stated, “We are excited to attend this year’s BIO right
on the heels of an extraordinarily productive working session at
ASCO with a host of renowned oncologists who were introduced to our
Cell-in-a-Box® therapy for pancreatic cancer. Their input has
resulted in further refinement of the design of our Phase 2b
clinical trial, which we’ll explain to those we meet with at BIO.
We have attracted considerable interest of late in the biotech
sector and plan to capitalize on this while here in San Francisco.
We have a golden opportunity for the world to learn more about
PharmaCyte’s novel therapies for cancer and diabetes than ever
before, and to learn why we believe they will have such a positive
impact on patients who suffer from these dreadful diseases.”
BIO is the world’s largest biotechnology gathering. Over 40,000
people are expected to attend this year. BIO features 1,800
exhibitors and 55 regional and international pavilions, with 8
specialized product focus zones. BIO attracts over 15,000
biotechnology and pharma leaders who come together for intensive
networking to discover new opportunities and promising
partnerships. The event covers a wide spectrum of life science
applications, such as cell therapy and drug discovery. BIO allows
companies like PharmaCyte the opportunity to interact with
influential decision makers and high-level executives that come to
BIO to discover new therapies in the biotechnology sector, evaluate
emerging technologies and form new partnerships.
About PharmaCyte BiotechPharmaCyte Biotech is a
clinical stage biotechnology company developing and preparing to
commercialize treatments for cancer and diabetes based upon a
proprietary cellulose-based live cell encapsulation technology
known as “Cell-in-a-Box®.” This technology will be used as a
platform upon which treatments for several types of cancer and
diabetes are being developed. PharmaCyte’s treatment for cancer
involves encapsulating genetically modified live cells that convert
an inactive chemotherapy drug into its active or “cancer-killing”
form. These encapsulated live cells are placed as close to a
cancerous tumor as possible. Once implanted in a patient, a
chemotherapy drug which needs to be activated in the body
(ifosfamide) is then given intravenously at one-third the normal
dose. The ifosfamide is carried by the circulatory system to where
the encapsulated cells have been placed. When the ifosfamide, which
is normally activated in the liver, comes in contact with the
encapsulated live cells, activation of the chemotherapy drug takes
place at the source of the cancer without any side effects from the
chemotherapy. This “targeted chemotherapy” has proven remarkably
effective and safe to use in past clinical trials.
In addition to developing a novel treatment for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and insulin-dependent Type 2 diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and release insulin in response to the levels of
blood sugar in the human body. The encapsulation will be done using
the Cell-in-a-Box® technology.
Safe Harbor This press release may contain
forward-looking statements regarding PharmaCyte Biotech and its
future events and results that involve inherent risks and
uncertainties. The words "anticipate", "believe", "estimate",
"expect", "intend", "plan" and similar expressions, as they relate
to PharmaCyte or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte, could cause actual results to
differ materially from those set forth in the forward-looking
statements. They include PharmaCyte's ability to continue as a
going concern, delays or unsuccessful results in preclinical and
clinical trials, flaws or defects regarding its product candidates,
changes in relevant legislation or regulatory requirements,
uncertainty of protection of PharmaCyte’s intellectual property and
PharmaCyte’s continued ability to raise capital. PharmaCyte does
not assume any obligation to update any of these forward-looking
statements.
More information about PharmaCyte can be found
at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com